Literature DB >> 20190905

Adderall and cardiovascular risk: A therapeutic dilemma.

Tangu Sichilima1, Michael J Rieder.   

Abstract

Year:  2009        PMID： 20190905      PMCID： PMC2690554          DOI： 10.1093/pch/14.3.193

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  10 in total

Review 1.  Stimulants and sudden death: what is a physician to do?

Authors:  Timothy E Wilens; Jefferson B Prince; Thomas J Spencer; Joseph Biederman
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

2.  ADHD drugs and cardiovascular risk.

Authors:  Steven E Nissen
Journal:  N Engl J Med       Date:  2006-03-20       Impact factor: 91.245

3.  Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children.

Authors:  Robert L Findling; Joseph Biederman; Timothy E Wilens; Thomas J Spencer; James J McGough; Frank A Lopez; Simon J Tulloch
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

4.  Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.

Authors:  Joshua A Samuels; Kathy Franco; Fiona Wan; Jonathan M Sorof
Journal:  Pediatr Nephrol       Date:  2005-10-28       Impact factor: 3.714

5.  Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD.

Authors:  James J McGough; Joseph Biederman; Sharon B Wigal; Frank A Lopez; James T McCracken; Thomas Spencer; Yuxin Zhang; Simon J Tulloch
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-06       Impact factor: 8.829

6.  A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

Authors:  W E Pelham; H R Aronoff; J K Midlam; C J Shapiro; E M Gnagy; A M Chronis; A N Onyango; G Forehand; A Nguyen; J Waxmonsky
Journal:  Pediatrics       Date:  1999-04       Impact factor: 7.124

7.  An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension.

Authors:  Timothy E Wilens; Randall M Zusman; Paul G Hammerness; Amy Podolski; Julia Whitley; Thomas J Spencer; Martin Gignac; Joseph Biederman
Journal:  J Clin Psychiatry       Date:  2006-05       Impact factor: 4.384

8.  A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder.

Authors:  Joseph Biederman; Frank A Lopez; Samuel W Boellner; Mark C Chandler
Journal:  Pediatrics       Date:  2002-08       Impact factor: 7.124

Review 9.  Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update.

Authors:  Guilherme Polanczyk; Peter Jensen
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-04

10.  Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis.

Authors:  Stephen V Faraone; Joseph Biederman; Christine Roe
Journal:  J Clin Psychopharmacol       Date:  2002-10       Impact factor: 3.153
  10 in total
  2 in total

1.  Prescriptions, nonmedical use, and emergency department visits involving prescription stimulants.

Authors:  Lian-Yu Chen; Rosa M Crum; Eric C Strain; G Caleb Alexander; Christopher Kaufmann; Ramin Mojtabai
Journal:  J Clin Psychiatry       Date:  2016-03       Impact factor: 4.384

2.  Oral aniracetam treatment in C57BL/6J mice without pre-existing cognitive dysfunction reveals no changes in learning, memory, anxiety or stereotypy.

Authors:  Conner D Reynolds; Taylor S Jefferson; Meagan Volquardsen; Ashvini Pandian; Gregory D Smith; Andrew J Holley; Joaquin N Lugo
Journal:  F1000Res       Date:  2017-08-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.